Sai Life Sciences Ltd (SAILIFE) is currently trading at 1,552.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sai Life Sciences is an integrated CRDMO providing end-to-end discovery, development and commercial manufacturing services to global pharmaceutical and biotechnology innovators, operating discovery and R&D labs in Boston and Manchester plus large GMP manufacturing and R&D campuses in India. Q3 FY26 revenue was ₹556 crore (+27% YoY) and 9MFY26 revenue reached ₹1,590 crore (+43% YoY); EBITDA margin expanded to 34% in Q3 and 30% for 9MFY26, driven by operating leverage on employee costs and improved material margins. The company is executing a substantial expansion program (FY26 capex plan ~₹700 crore, ₹405 crore invested so far) to nearly double reactor capacity to 1,150 KL and add major Process R&D, peptide pilot, and OEB‑6 containment labs, targeting commercial scale for new modalities. Sai is shifting beyond commodity CDMO work into next-generation modalities—peptides, ADC payloads, oligonucleotides and TPDs—while embedding AI/ML, photochemistry, flow, and electrochemistry into discovery and CMC workflows to accelerate timelines and win strategic, large‑pharma partnerships.

Over the past 52 weeks, Sai Life Sciences Ltd has traded between a low of ₹786.15 and a high of ₹1,697.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sai Life Sciences Ltd has a market capitalization of approximately 33,668.73. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sai Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 93.07 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 33,668.73 Cr, Sai Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sai Life Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sai Life Sciences Ltd is 93.07. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board meeting to consider and approve Q1 FY27 unaudited results is scheduled for August 6, 2026.

The Board of Directors is scheduled to meet on August 6, 2026, to consider and approve the unaudited results for the quarter ended June 30, 2026.

Pharma shares gained after the Pentagon named WuXi AppTec on a list of firms associated with the Chinese military, which investors viewed as supportive for India-based outsourcing alternatives.

It reported revenue growth of 36%, EBITDA growth of 43%, and net profit growth of 100% for Q2 and the half year ended September 2025.